CD44 and neoplasm: We showed that CD44, FN1, and MMP9 were downregulated after both FUS-DDIT3 expression and ruxolitinib treatment, and decreased expression of CD44 (60), MMP9 (61), and FN1 (62) has also been observed in other tumor types after JAK-STAT inhibition.